
JPXHealthcareMedical - Instruments & Supplies
Latest quote
¥1,438.5
−¥7.50 · -0.52%
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
Latest quote
¥1,438.5
−¥7.50 · -0.52%
Regular session · JST · Market data may be delayed.
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
Day range
Current ¥1,438.5
52-week range
Current ¥1,438.5
Regular session · JST · Market data may be delayed.
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
Day range
Current ¥1,438.5
52-week range
Current ¥1,438.5
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 660.54B JPY | 644.59B JPY | 586.79B JPY | 545.2B JPY | 494.79B JPY |
| Cost of goods sold | 452.26B JPY | 450.93B JPY | 412.81B JPY | 379.3B JPY | 342.95B JPY |
| Gross profit | 208.28B JPY | 193.66B JPY | 173.98B JPY | 165.9B JPY | 151.84B JPY |
| Research and development | — | 21.67B JPY | 20.85B JPY | 19.67B JPY | 18.73B JPY |
| Selling, general, and administrative | 170.66B JPY | 145.39B JPY | 130.8B JPY | 128.5B JPY | 109.22B JPY |
| Operating expenses | 170.66B JPY | 167.06B JPY | 151.64B JPY | 148.17B JPY | 127.95B JPY |
| Interest income | 2.21B JPY | 2.18B JPY | 1.58B JPY | 1.1B JPY | 669M JPY |
| Interest expense | 9.77B JPY | 7.84B JPY | 6.53B JPY | 4.5B JPY | 4.19B JPY |
| Depreciation and amortization | 63.74B JPY | 65.65B JPY | 58.87B JPY | 48.74B JPY | 46.16B JPY |
| Operating income | 37.63B JPY | 26.6B JPY | 22.34B JPY | 17.73B JPY | 23.88B JPY |
| Net income | 13.5B JPY | 5.11B JPY | 11.11B JPY | 4.58B JPY | 13.46B JPY |
Company facts updated Sep 11, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 28, 2011 | 2:1 | — | — |
Effective Sep 28, 2011
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T623.8M0.02%2.91T JPY0.05%¥413.5-0.48%
Avantis International Small Cap Value ETFAVDV42.94M0.21%20.51B USD0.36%$111.44+0.56%
Vanguard Total International Stock ETFVXUS22.36M0.00%646.2B USD0.05%$87.045+0.89%
Vanguard FTSE Developed Markets ETFVEA15.14M0.00%315B USD0.03%$72.665+1.04%
iShares Core MSCI EAFE ETFIEFA10.61M0.01%193.07B USD0.07%$99.425+0.93%
iShares MSCI EAFE Small-Cap ETFSCZ4.88M0.04%12.89B USD0.40%$85.98+0.74%
Dimensional - International Small Cap Value ETFDISV4.38M0.08%5.24B USD0.42%$44.34+0.57%
Vanguard FTSE All-World ex-US ETFVEU3.51M0.00%95.9B USD0.04%$85.115+0.97%
iShares Core TOPIX ETF1475.T
Avantis International Small Cap Value ETFAVDV
Vanguard Total International Stock ETFVXUS
Vanguard FTSE Developed Markets ETFVEA
iShares Core MSCI EAFE ETFIEFA
iShares MSCI EAFE Small-Cap ETFSCZ
Dimensional - International Small Cap Value ETFDISV
Vanguard FTSE All-World ex-US ETFVEUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.